I am proud to be one of the driving forces behind the psychedelics renaissance which is seeing compounds such as psilocybin (“magic mushrooms”), ibogaine, and DMT being explored as potential treatments for a wide range of mental health conditions. In 2018, I founded atai Life Sciences, which listed on Nasdaq with an IPO in June 2021, and currently has a pipeline of more than 8 therapeutic candidates targeted at the world’s most prevalent and damaging mental health illnesses, including depression, PTSD, anxiety, and addiction.
Beyond atai, Apeiron has a broad portfolio of companies in the mental health & neuroscience field, from depression treatments to new solutions for Alzheimer’s disease and dementia.
Or the various podcasts with Christian, which you find in the press coverage section.
